Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies

• Published in: CNS neuroscience & therapeutics Vol. 27; no. 3; pp. 270 - 279
• Main Authors: Zhao, Na, Yang, Yuan, Zhang, Ling, Zhang, Qinge, Balbuena, Lloyd, Ungvari, Gabor S., Zang, Yu‐Feng, Xiang, Yu‐Tao
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.03.2021; John Wiley and Sons Inc
• Subjects: Case-Control Studies; comparative study; Cross-Sectional Studies; Humans; Meta-analysis; Movement disorders; Neurodegenerative diseases; Parkinson Disease - diagnosis; Parkinson Disease - psychology; Parkinson Disease - therapy; Parkinson's disease; Quality of life; Quality of Life - psychology; Questionnaires; Review; Systematic review; Sweden; Turkey; United Kingdom > UK; United States > US; Europe; meta-analysis; comparative study; Parkinson's disease; quality of life
• ISSN: 1755-5930; 1755-5949; 1755-5949
• DOI: 10.1111/cns.13549

Background Studies regarding the impact of Parkinson's disease (PD) on quality of life (QOL) have reported conflicting results, and the underlying QOL domains require further study. In order to understand the association between PD and QOL, we conducted this meta‐analysis to systematically compare QOL between PD patients and healthy controls. Method The PubMed, PsycINFO, EMBASE, and Web of Science databases were systematically searched. Data were analyzed using the random‐effects model. Results Twenty studies covering 2707 PD patients and 150,661 healthy controls were included in the study. Compared with healthy controls, PD patients had significantly poorer QOL overall and in most domains with moderate to large effects sizes. Different QOL measures varied in their association with quality of life, with the Parkinson's Disease Questionnaire‐39 (PDQ‐39) having the largest effect size (standard mean difference, SMD = −1.384, 95% CI: −1.607, −1.162, Z = 12.189, P < 0.001), followed by the Europe Quality of Life Questionnaire‐visual analogue scale (EQ‐VAS) (SMD = −1.081, 95% CI: −1.578, −0.584, Z = −4.265, P < 0.001), Europe Quality of Life Questionnaire‐5D (EQ‐5D) (SMD = −0.889, 95% CI: −1.181, −0.596, Z = −5.962, P < 0.001), and the Short‐form Health Survey (SF) scales (physical dimension: SMD = −0.826, 95% CI: −1.529, −0.123, Z = −2.303, P = 0.021; mental dimension: SMD = −0.376, 95% CI: −0.732, −0.019, Z = −2.064, P = 0.039). Conclusion PD patients had lower QOL compared with healthy controls in most domains, especially in physical function and mental health. Considering the negative impact of poor QOL on daily life and functional outcomes, effective measures should be developed to improve QOL in this population. Improving the QOL in patients with PD is an important concern, which can provide reference for decisions of policymakers and clinicians. PD patients had significantly poorer QOL, with moderate to large effect sizes in most domains. Moreover, different QOL measures had moderating effects on the results.